- 1 **Title:** Maternal and neonatal IgG against *Klebsiella pneumoniae* are associated with broad 2 protection from neonatal sepsis: a case-control study of hospitalized neonates in Botswana
- 3
- 4 Authors: Siqi Linsey Zhang^{*1}, Carolyn M. McGann^{*2,6}, Tereza Duranova¹, Jonathan Strysko^{3,4,6},
- 5 Andrew P. Steenhoff^{1,4,6}, Alemayehu Gezmu⁵, Britt Nakstad⁵, Tonya Arscott-Mills^{3,4}, One
- 6 Bayani⁵, Banno Moorad⁴, Nametso Tlhako⁴, Melissa Richard-Greenblatt^{7,8}, Paul J. Planet^{1,6}, Susan
- 7 E. Coffin^{1,6}, Michael A. Silverman^{1,6}
- 8

9 Affiliation

- ¹Division of Infectious Diseases, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- ¹¹ ²Division of Neonatology, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- 12 ³Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- ⁴Botswana-University of Pennsylvania Partnership, Gaborone, Botswana
- 14 ⁵Faculties of Medicine & Health Sciences, Department of Paediatric & Adolescent Health,
- 15 University of Botswana, Gaborone, Botswana
- 16 ⁶Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 17 ⁷Hospital for Sick Children, Toronto, Canada
- 18 ⁸Department of Laboratory and Pathobiology, University of Toronto, Canada
- 19 *These authors contributed equally to this paper
- 20

21 ABSTRACT

- 22 Sepsis is the leading postnatal cause of neonatal mortality worldwide. Globally Klebsiella
- 23 *pneumoniae* is the leading cause of sepsis in hospitalized neonates. This study reports
- development and evaluation of ELISA for anti-*Klebsiella* IgG using dried blood spot samples and
- evaluates the association of anti-*Klebsiella* IgG (anti-Kleb IgG) antibodies in maternal and neonatal samples and the risk of neonatal sepsis. Neonates and their mothers were enrolled at 0-
- 27 96 hours of life in the neonatal unit of a tertiary referral hospital in Gaborone. Botswana and
- 28 followed until death or discharge to assess for episodes of blood culture-confirmed neonatal sepsis.
- 29 Neonates with sepsis had significantly lower levels of *Kleb*-IgG compared to neonates who did
- 30 not develop sepsis (Mann-Whitney U, p=0.012). Similarly, samples from mothers of neonates who
- 31 developed sepsis tended to have less Kleb-IgG compared to mothers of controls (p=0.06). The
- 32 inverse correlation between *Kleb-IgG* levels and all-cause bacteremia suggests that maternal *Kleb-*
- 33 IgG is broadly protective through cross-reactivity with common bacterial epitopes. These data
- 34 support the continued use of immunoglobulin assays using DBS samples to explore the role of
- 35 passive immunity on neonatal sepsis risk and reaffirm the critical need for research supporting the
- 36 development of maternal vaccines for neonatal sepsis.

38 INTRODUCTION

39 Sepsis is the leading postnatal cause of neonatal deaths, accounting for nearly one million deaths 40 annually.(1) The incidence, causative pathogens and mortality attributable to neonatal sepsis vary 41 globally.(2) In high-income countries, the most common causes of early-onset sepsis (EOS) are 42 Group B streptococcus (GBS) and Escherichia coli whereas the vast majority of late-onset sepsis 43 (LOS) cases are caused by Gram-positive organisms such as coagulase-negative staphylococci 44 (CoNS) and Staphylococcus aureus.(3-5) In contrast, both EOS and LOS are predominantly 45 caused by Gram-negative organisms in low- and middle-income countries (LMIC).(6-8) In 46 Botswana and other sub-Saharan African countries, Gram-negative sepsis accounts for about 60% 47 of neonatal sepsis, with a predominance of Klebsiella spp.(9-11) Notably, over three-quarters of 48 the global neonatal sepsis deaths occur in LMIC signifying the critical unmet need to better 49 understand the immune system features that predispose to, or protect against neonatal sepsis in 50 these settings.(12) There has been a global focus on strategies to prevent neonatal infection, particularly GBS, including prophylactic antibiotics and a novel vaccine; however, geographic 51 52 variation in the causes of neonatal infections highlights the need to better understand the risk 53 factors for Gram-negative sepsis in neonates.

Since neonatal innate and adaptive immune systems are immature at birth, the immunoglobulins obtained through transplacental transfer and breastmilk provide critical protection from sepsis.(13-16) Immunoglobulin G (IgG) is the primary antibody transplacentally transferred and plays an essential role in protecting neonates from infection.(17, 18) Although the transfer of IgG begins at 13 weeks of gestation, it accelerates significantly after 36 weeks. Thus preterm, as compared to term, neonates are less protected by passive immunity contributing to their higher risk of sepsis.(18, 19)

We hypothesized that lack of maternal IgG antibodies that target specific pathogenic bacteria may predispose neonates to develop sepsis. We developed an enzyme-linked immunosorbent assay (ELISA) to evaluate the degree to which the risk of neonatal sepsis is associated with the level of IgG from maternal and neonatal serum capable of binding *K*. *pneumoniae* (*Kleb*-IgG).

66

67 **METHODS**

68 Setting and population

69 This study used samples collected from a cohort of 467 neonates admitted to the neonatal unit at a 70 tertiary referral hospital in Gaborone, Botswana from November 1, 2020 – December 31, 2021. 71 Participants were eligible for enrollment in the parent study if admitted to the neonatal unit within 72 3 days of life and were followed until discharge or death. A research nurse approached mothers 73 after delivery to obtain written informed consent in Setswana or English. The study was approved 74 by the institutional review boards of the Botswana Ministry of Health Research and Development 75 Committee (protocol 13/18/1, Jan. 16, 2020), the University of Botswana (protocol 147, Dec. 13, 76 2019), the University of Pennsylvania (protocol 833786, April 22, 2020), the hospital IRB 77 (protocol 708, April 2, 2020) and Children's Hospital of Philadelphia (protocol 19-016848, July 78 25, 2020). Cases of sepsis were matched with controls also admitted to the neonatal unit but 79 without sepsis in a 1:4 ratio based on nearest sample collection date and gestational age. Subjects 80 unable to be matched by GA were matched with the nearest GA. Subjects with missing data or 81 samples were excluded. Patients and the public were not included in the design or implementation 82 of this study.

84 Sample collection

85 Dried blood spots (DBS) were collected by heel stick from enrolled neonates and finger stick from 86 mothers timed with a clinically indicated blood sample and stored on filter paper (Whatman 903, 87 Cytiva, USA). We were unable to stick a second time if a patient stopped bleeding, thus collected 88 volumes varied. Blood spots were dried at room temperature for three hours and placed in plastic 89 bags with desiccant packs. They were stored at room temperature before shipment (13-26°C) and 90 at -20°C after shipment from Botswana to the United States to enhance stability of the samples. 91 Samples were transported at room temperature in two shipments: the first was shipped 6-8 months 92 after collection date and the second shipment contained both neonatal and maternal DBS collected 93 within 4 months. Sample integrity was established prior to analysis.

94 Blood cultures were drawn at the discretion of the clinical team for suspected clinical sepsis 95 using conventional clinical criteria.(20) Samples were incubated on an automated blood culture 96 system (BACT/ALERT, bioMerieux, Marcy l'Etoile, France) for up to 5 days or until blood culture 97 positivity. Neonatal sepsis was defined as a positive blood culture. CoNS spp. and other skin 98 commensals were deemed contaminants unless ≥2 cultures within 7 days grew this organism.(21) 99

100 Extraction of antibodies from dried blood spots

To extract antibodies from DBS, a 6.35-mm-diameter punch of a saturated blood spot was placed in an Eppendorf tube with 500 μ l of elution buffer (phosphate buffered saline [PBS] with 0.1% BSA and protease inhibitor cocktail, Roche, catalog no. 04693159001) then were incubated overnight on a shaker at 4°C. Samples were then centrifuged for 5 mins at 8,000g at 4°C to pellet debris and the supernatants were collected and stored at -20°C.

107 Immunoglobulin quantification for DBS eluates

To quantify the total amount of IgG and IgA present in each eluate, ELISA was performed using
Bethyl Human ELISA Quantitation Set (E80-100, E80-102, E80-104) per manufacturer
instructions (Bethyl Laboratories, Montgomery, TX, USA).

111

112 Bacterial-binding IgG quantification for DBS eluates using ELISA

113 We developed an ELISA using bacteria-coated plates to determine the degree to which neonatal 114 antibodies bind to bacterial surface epitopes of Klebsiella pneumoniae isolate MF391. This isolate 115 was obtained from a blood culture sample in Botswana. The isolate was subcultured to a Luria 116 broth (LB) solid media and incubated at 37°C overnight. A single colony was selected and 117 transferred to 5 mL of LB to establish a liquid culture. The following day, the culture was 118 centrifuged (10-minute at 4,000xg), fixed with 4% paraformaldehyde for 20 minutes and washed 119 three times in PBS (pH 7.4). The pellet was resuspended in PBS and diluted to achieve an optical 120 density of 1.0. A 100 µl volume of bacteria was added to each well of a 96-well ELISA plate 121 (Thermo Scientific Nunc, 442404). The plate was incubated overnight at 4°C then washed (0.07 122 M NaCl and 0.025% Tween 20 dissolved in Tris buffer) and blocked (0.007 M NaCl and 1% BSA 123 in Tris) for 30 minutes at room temperature. DBS eluates were diluted (0.007 M NaCl, 1% BSA, 124 0.025% Tween 20 in Tris buffer) to a uniform IgG concentration of 0.4 ng/µl. 100 µl of the diluted 125 DBS samples were added to each well and incubated overnight at 4°C. The wells were then washed 126 and incubated with horseradish peroxidase-conjugated anti-IgG antibody (1 mg/ml diluted 127 1:150,000) for an hour and developed for 15 minutes in 3,3',5,5'-tetramethylbenzidine (TMB) with 128 $0.18M H_2SO_4$ as the stopping reagent. The absorbance at 450nm was measured immediately on an 129 Enspire Multimode Plate Reader.

130 A standard unit (SU) was established using reference serum from a healthy adult to 131 establish a standard curve to normalize all samples. A standard ELISA was used to determine the 132 IgG concentration of this serum sample. The sample was then serially diluted to create a standard 133 curve for each experiment. We defined one SU as the optical density of 0.5 µg/mL IgG of the 134 reference serum. Due to variability in the amount of blood collected on each card, we normalized 135 the microbial ELISA assay by adding the same amount of IgG (i.e., 50 ng, an amount determined 136 by titration experiments) to each well to determine the relative amount of Klebsiella-binding IgG antibodies from each sample. 137

To determine the amount of IgG binding to common bacterial epitopes, we used *E. coli*lipopolysaccharide and *Salmonella typhimurium* flagellin. A 100 μl volume of diluted flagellin or
LPS (1 μg/mL) was added to each well of a 96-well ELISA plate and incubated overnight at 4°C.
The remainder of the ELISA was performed as described above. The secondary anti-LPS and antiflagellin antibodies were diluted 1:5000.

143

144 Statistical analysis

Nonparametric Mann-Whitney U tests were used to compare *Kleb*-IgG levels and demographic characteristics between neonates with sepsis and healthy controls. A Kruskal-Wallis test was used to compare gestational age categories between the two groups. Simple linear regression was used to evaluate trends in antibody levels. We conducted an exploratory analysis using logistic regression to evaluate the association of *Kleb*-IgG levels with sepsis while controlling for both gestational age and days from storage to sample analysis. We conducted an additional exploratory analysis using simple linear regression to explore the association between maternal and neonatal

- 152 antibody levels among neonates with and without sepsis to evaluate whether antibody transfer
- 153 differed. Results were considered significant using a two-sided p value (p<0.05).
- 154
- 155 **RESULTS**

156 Study participant characteristics

- 157 Of the 467 patients enrolled, 30 (6%) experienced bloodstream infections, 116 (24%) had neonatal
- 158 DBS shipped recently and available for analysis of whom 8 were diagnosed with sepsis (Fig. 1).
- 159 The most common organisms cultured from the neonates with sepsis were Acinetobacter spp. and
- 160 *Klebsiella* spp. which was similar to the etiologies of sepsis in the parent study (Fig. 1). Cases
- 161 were matched with controls by gestational age and sample collection dates. Gestational age
- 162 remained significantly different between groups, but they were otherwise similar (Table 1). Three
- 163 neonates were missing paired maternal samples and were excluded from maternal antibody
- 164 analyses.

Figure 1. Enrollment numbers, sample numbers, and causes of sepsis in overall cohort and
 samples included in this analysis. CoNS= Coagulase negative *Staphyloccus spp.*; MRSA=
 methicillin resistant *Staphylococcus aureus*

168

169 Table 1. Summary of demographic variables for neonatal sepsis and control groups.

170

Variable	Sepsis cases	Controls (n=32)	p value
	(n=8)	(-)	
Female sex, n (%)	4 (50)	14 (44)	0.75
Maternal HIV positive, n (%)	2 (25)	10 (31)	0.73
C-section, n (%)	1 (13)	11 (34)	0.23
Parity, median	1	2	0.56
Gestational age, median	29.5	35.5	0.01
Sample collection to analysis, days, median	69	79	0.52

171

172 Establishing DBS sample integrity

173 Establishing whether DBS cards stored at room temperature provide valid data is important for 174 studies in settings where immediate storage at -20°C may be unavailable. Prior research 175 demonstrated that most proteins on DBS cards stored at room temperature start degrading after 4 176 weeks but remain valid for most applications for roughly 6 months, while certain proteins can be 177 detected after much longer periods of storage.(22-24) We, therefore, included the samples with <178 4 months of storage at room temperature in this analysis. We evaluated the concentration of total 179 IgG and *Kleb*-IgG from each sample since sample collection to estimate the degree of antibody 180 degradation over time. We recovered lower IgG concentration over time from DBS samples (Fig. 181 2A). As such we normalized the amount of total IgG in each sample. Therefore, we did not observe 182 a decrease in *Kleb*-IgG over time (Fig. 2B). Degradation of samples during room temperature 183 storage was similar in cases compared to controls (Fig. S1). 184 Figure 2. IgG concentration in DBS samples collected within 4 months. A) Total IgG

Figure 2. IgG concentration in DBS samples collected within 4 months. A) Total IgG concentration recovered from each sample as a function of time interval between sample collection and extraction. B) Relative amount of *Kleb*-IgG in each DBS sample, normalized to $0.4 \text{ng/}\mu\text{L}$ of total IgG, as a function of time interval between sample collection and extraction. Standard Unit (SU). Simple linear regression.

189

Supplementary Figure 1. Immunoglobulin levels over time in cases compared to controls. A) Total IgG concentration recovered from each sample as a function of time interval between sample collection and extraction in sepsis cases compared to controls. B) Relative amount of *Kleb*-IgG in each DBS sample as a function of time interval between sample collection and extraction. Standard Unit (SU). Slopes were compared by analysis of covariance.

195

As a quality check for both maternal and neonatal sample integrity, we quantified the amount of immunoglobulin A (IgA) recovered from DBS. IgA is not transplacentally transferred nor is it produced by neonates in the first weeks of life. As predicted, maternal DBS samples had detectable serum concentrations of IgA while IgA was not detected in any neonatal samples (**Fig.**

200 **S2**).

201

Supplementary Figure 2. Levels of IgA in maternal and neonatal DBS samples. IgA level was
 determined using standard human ELISA from randomly selected paired maternal and neonatal
 samples. Mann-Whitney U test. **p<0.01.

205

206 Neonates with laboratory-confirmed sepsis have lower levels of *Kleb*-IgG

207 We next investigated whether levels of maternal and neonatal *Kleb*-IgG were associated with 208 increased risk for neonatal sepsis in this cohort of 8 neonates with sepsis and 32 controls without 209 sepsis. We found significantly lower levels of Kleb-IgG in neonates who developed sepsis 210 compared to neonates who did not develop sepsis (p=0.012, Fig. 3A). Kleb-IgG levels were lower 211 in neonates with sepsis regardless of etiology of sepsis (p=0.04) and not significantly different in 212 samples from neonates with sepsis due to *Klebsiella* compared to other pathogens (Fig. 3B). Since neonatal IgG concentration and specificities reflect maternal serum IgG, we compared the Kleb-213 214 IgG levels in samples from mothers of neonates with and without sepsis; samples from mothers of 215 neonates who developed sepsis tended to have less Kleb-IgG compared to mothers of controls 216 (p=0.06, **Fig. 3C**). Overall, neonatal and maternal *Kleb*-IgG levels were correlated (r=0.27, p<0.01, 217 data not shown). In an exploratory analysis, we unexpectedly observed that there appeared to be 218 an inverse relationship between neonatal and maternal *Kleb*-IgG in dyad samples from patients 219 with sepsis while a positive association was apparent between neonatal and maternal *Kleb*-IgG

220 levels in those without sepsis. (Fig. S3).

221

Figure 3. *Kleb*-IgG in neonatal and maternal samples of cases with sepsis compared to controls. A-B) *Kleb*-IgG binding in neonates who developed sepsis compared to matched controls. Data were normalized to standard unit, defined as the amount of *Kleb*-IgG in 100 μ l of reference serum (healthy adult) with 0.5 μ g/mL IgG. Mann-Whitney U test (*p <.05). C) *Kleb*-IgG binding in serum from mothers of neonates who developed sepsis compared to mothers of controls. Kruskal Wallis test (*p<0.05).

Supplementary Figure 3. Correlation between maternal *Kleb*-IgG and neonatal *Kleb*-IgG
levels. A) *Kleb*-IgG levels for mother-neonate dyads with sepsis, simple linear regression, p=0.32.
B) *Kleb*-IgG levels for mother-neonate dyads with sepsis, simple linear regression, p<0.01.

- 233 The association of low Kleb-IgG levels with risk for neonatal sepsis from Klebsiella or 234 other bacteria (Fig. 3B) suggests that Kleb-IgG is likely non-specific and may offer protection 235 through cross-reactivity with common bacterial epitopes. Recent murine studies demonstrated that 236 serum IgG antibodies that bind to commensal microbes protect against bacteremia from pathogenic 237 bacteria.(25, 26) LPS is the most abundant surface molecule in most Gram-negative bacteria, and 238 anti-LPS IgG antibodies can bind to LPS on a variety of microbes.(27) The levels of anti-LPS 239 antibodies are associated with the risk for developing sepsis.(28) Similarly, flagellin is a virulence 240 factor present on many bacteria and a common IgG-targeted epitope. Thus, we evaluated the 241 degree to which IgG from each sample binds to lipopolysaccharides (LPS) and flagellin. We found 242 similar levels of anti-LPS IgG antibodies and anti-flagellin IgG antibodies in neonates with sepsis 243 compared to controls (Fig. S4). There was no association of *Kleb*-IgG levels with other potential 244 confounders including sex, parity, maternal HIV status, or delivery mode (Fig. S5). 245 Supplementary Figure 4. Anti-LPS IgG and anti-flagellin IgG in neonates with and without 246 sepsis. A) ELISA comparing anti-LPS IgG in neonates with sepsis vs. controls. All units are 247 normalized to the standard unit, defined as the amount of anti-LPS IgG in 50 ng of reference adult 248 serum. B) ELISA comparing anti-flagellin IgG in neonates with sepsis vs. controls. Mann-Whitney 249 U test. 250 251 Supplementary Figure 5. *Kleb*-IgG level by maternal HIV status, neonatal sex, delivery mode, 252 and maternal parity. A-D) Kleb-IgG binding comparison by the indicated clinical 253 variables. Mann-Whitney U test or Kruskal-Wallis test. 254 255 Low *Kleb*-IgG levels are associated with neonatal sepsis across gestational ages
- 256 Given the differences in median gestational age in controls and sepsis cases, we performed
- a stratified analysis and found that neonates born at <33 weeks have significantly lower *Kleb*-IgG

levels compared to neonates born at \geq 37 weeks (p=0.03) (**Fig. 4A**). We evaluated this association in cases compared to controls and found no statistically significant difference in *Kleb*-IgG levels in premature neonates with sepsis compared to controls, yet a trend towards lower levels samples from neonates born at <33 weeks and between 33-37 weeks (**Fig. 4B**). Indeed, in an adjusted analysis, *Kleb*-IgG was associated with a decreased odds ratio (OR) of neonatal sepsis when adjusting for gestational age and days since sample collection (aOR 0.49, 95% CI [0.18, 0.93]). These analyses indicate that low Kleb-IgG levels are associated with neonatal sepsis across

265 gestational ages.

Figure 4. *Kleb*-IgG level by gestational age. A) Comparison of *Kleb*-IgG binding in neonates
 stratified by gestational age. Kruskal Wallis and Mann-Whitney U test (*p<0.05). B) Comparison
 of *Kleb*-IgG binding in neonates with sepsis compared to controls, stratified by gestational age.
 Mann-Whitney U test.

270

271 **DISCUSSION**

We report an association between the level of neonatal and maternal serum IgG that bind to *K. pneumoniae* and all-cause laboratory-confirmed neonatal sepsis in a cohort of hospitalized neonates in Botswana. Using an ELISA to detect serum antibody reactivity to a *K. pneumoniae* blood culture isolate from Gaborone, Botswana, we found that neonates who developed sepsis and their mothers have lower levels of *Kleb*-IgG compared to controls when adjusting for gestational age and days of sample storage.

K. pneumoniae was historically the predominant isolate in blood cultures at this site,(7)
leading to the development of an ELISA against a *K. pneumoniae* isolate from this NICU. During
enrollment, the epidemiology of neonatal sepsis shifted from predominantly *Klebsiella* spp. to a
more diverse set of microbes (Fig. 1). Remarkably, neonates with sepsis due to non-*Klebsiella*bacteria also have lower *Kleb*-IgG compared to controls suggesting that *Kleb*-IgG might provide

cross-protection against common bacterial epitopes. However, neither anti-LPS nor anti-flagellin IgG antibody levels differed between neonates with sepsis compared to controls, which argues against either being an important cross-reactive microbial epitope in this cohort. These findings suggest the possibility that cross-reactivity to other common epitopes or that multiple epitopes function together to provide protection from neonatal sepsis from a range of pathogens.

288 By standardizing the total amount of IgG analyzed from each DBS sample, we expected to 289 recover similar levels of Kleb-IgG across gestational ages, as we assumed that total IgG and 290 pathogen-specific IgG would cross the placenta at the same rate. However, Kleb-IgG levels were 291 lower in preterm neonates which may result from colonization with *Klebsiella* spp. later in 292 pregnancy or increased production of anti-commensal antibodies later in gestation. Klebsiella 293 antibodies may vary among pregnant people due to prior infections and differential abundance in 294 the microbiome based on exposure, antibiotics, and other factors. (29) Similarly, Stach et al 295 reported increased Kleb-IgG with increasing birthweight, a variable that is often colinear with 296 gestational age.(30) Interestingly, another study focusing on pathogen-specific antibodies found 297 no difference in anti-Klebsiella IgG by gestational age category.(31) Neither of these studies 298 reported sepsis as an outcome.

Although there were lower levels of *Kleb*-IgG in preterm neonates in our study, the risk of sepsis remained significant when adjusting for GA and days since sample collection indicating that prematurity alone does not explain the association between lower *Kleb*-IgG levels and neonatal sepsis. Since the rate of sample degradation was similar between cases and controls, this is unlikely to account for the association (**Fig. S1**). In an exploratory analysis, we noted a positive linear correlation of maternal and neonatal *Kleb*-IgG among the whole cohort regardless of gestational age, which has been reported previously.(31) However, when we separated cases and

306 controls, we noted an inverse correlation in dyads with sepsis and a positive correlation in control 307 dyads which may indicate different rates of placental transfer (**Fig. S3**). Many factors are known 308 to influence transplacental antibody transfer including parity, history of infections, timing of 309 vaccination and placental insufficiency.(14, 32) Data on placental health, prior infections and 310 maternal hypertension were not available in this cohort, thus we are unable to compare with these 311 findings.

Our study highlights the benefits of using DBS for sample collection. Compared to traditional blood tests, DBS can be obtained via minimally invasive methods (heel stick vs. venipuncture), requires a minimal blood volume, remains stable when stored at room temperature for up to 4 months, can be transported easily with minimal risk for contamination, and is an efficient and feasible method to acquire serum samples for a variety of assays.(33, 34) However, there are limitations including variation in collection volume and sample degradation which unfortunately limited the sample size in this study.

319

320 CONCLUSIONS

We propose that maternal IgG antibodies against *K. pneumoniae* are transferred *in utero* late in gestation and may be associated with a decreased risk of sepsis from diverse pathogens. These findings suggest species-specific maternal antibodies may confer broader protection against common neonatal pathogens. This supports the ongoing development of vaccination strategies during pregnancy to increase pathogen-binding IgG levels in neonates. Further studies are needed to explore mechanisms and enhance efficient transfer of protective antibodies to premature neonates.

329 Acknowledgements

330 The authors thank Mrs. Relebogile Thipe for helpful input with IRBs. The authors also thank the

331 study participants and their families, as well as the staff in the Neonatal Unit. This publication was

made possible through core services and support from the Penn Center for AIDS Research (CFAR),

an NIH-funded program (P30 AI 045008).

334

335 Contributorship Statement

336 S.Z. and C.M.M. contributed equally to this paper. Conceptualization, S.E.C., C.M.M., S.Z. and 337 M.A.S.; Methodology, S.Z. and T. D.; Writing – Original Draft, S.Z. and M.A.S.; Writing – 338 Review & Editing, S.Z., T.D., C.M.M., J.S., A.P.S., M.R.G., S.E.C. and M.A.S..; 339 Conceptualization of parent study, C.M.M., J.S., O.B., T.A-M., A.P.S., S.E.C.; Enrollment of 340 patients and data collection, J.S., B.M., N.T.; Provided care for study patients, J.S., B.N., O.B., 341 A.G.; Data review, S.Z., T.D., C.M.M., J.S., A.P.S., B.N., T.A-M., M.R-G., P.J.P., S.E.C., M.A.S; 342 Funding Acquisition, S.E.C., C.M.M., and M.A.S.; Resources, M.A.S.; Supervision, M.A.S. All 343 authors reviewed the final version of the manuscript prior to submission. 344

345 **Declaration of Interests**

- 346 We declare no financial conflict of interest.
- 347

348 **REFERENCES**

349

Rudd KE JS, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, Colombara DV, Ikuta KS,
 Kissoon N, Finfer S, Fleischmann-Struzek C, Machado FR, Reinhart KK, Rowan K, Seymour
 CW, Watson RS, West TE, Marinho F, Hay SI, Lozano R, Lopez AD, Angus DC, Murray CJL,
 Naghavi M Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for
 the Global Burden of Disease Study. Lancet. 2020;395(10219):200-11.

Fleischmann-Struzek C, Goldfarb DM, Schlattmann P, Schlapbach LJ, Reinhart K,
Kissoon N. The global burden of paediatric and neonatal sepsis: a systematic review. Lancet Respir
Med. 2018;6(3):223-30.

358 3. Shane AL, Stoll BJ. Neonatal sepsis: progress towards improved outcomes. J Infect.
359 2014;68 Suppl 1:S24-32.

360 4. Flannery DD, Mukhopadhyay S, Morales KH, Dhudasia MB, Passarella M, Gerber JS, et 361 al. Delivery Characteristics and the Risk of Early-Onset Neonatal Sepsis. Pediatrics. 2022;149(2).

362 5. Dong Y, Speer CP. Late-onset neonatal sepsis: recent developments. Arch Dis Child Fetal
363 Neonatal Ed. 2015;100(3):F257-63.

364 6. Wen SCH, Ezure Y, Rolley L, Spurling G, Lau CL, Riaz S, et al. Gram-negative neonatal
365 sepsis in low- And lower-middle-income countries and WHO empirical antibiotic
366 recommendations: A systematic review and meta-analysis. 2021;18:1-20.

- 367 7. Gezmu AM BA, Dramowski A, Bekker A, Aucamp M, Souda S, Nakstad B. Laboratory368 confirmed bloodstream infections in two large neonatal units in sub-Saharan Africa.
 369 2021;103:201-7.
- Sands K, Carvalho MJ, Portal E, Thomson K, Dyer C, Akpulu C, et al. Characterization of
 antimicrobial-resistant Gram-negative bacteria that cause neonatal sepsis in seven low- and
 middle-income countries. Nat Microbiol. 2021;6(4):512-23.

Wen SCH, Ezure Y, Rolley L, Spurling G, Lau CL, Riaz S, et al. Gram-negative neonatal
sepsis in low- and lower-middle-income countries and WHO empirical antibiotic
recommendations: A systematic review and meta-analysis. PLoS Med. 2021;18(9):e1003787.

- Mudzikati L, Dramowski A. Neonatal septicaemia: prevalence and antimicrobial
 susceptibility patterns of common pathogens at Princess Marina Hospital, Botswana. Southern
 African Journal of Infectious Diseases. 2015;30(3):108-13.
- 379 11. Gezmu AM, Bulabula ANH, Dramowski A, Bekker A, Aucamp M, Souda S, et al.
 380 Laboratory-confirmed bloodstream infections in two large neonatal units in sub-Saharan Africa.

381 Int J Infect Dis. 2021;103:201-7.

382 12. Global report on the epidemiology and burden of sepsis. In: WHO, editor. 2020.

Fu C, Lu L, Wu H, Shaman J, Cao Y, Fang F, et al. Placental antibody transfer efficiency
and maternal levels: specific for measles, coxsackievirus A16, enterovirus 71, poliomyelitis I-III
and HIV-1 antibodies. Sci Rep. 2016;6:38874.

14. Clements T, Rice TF, Vamvakas G, Barnett S, Barnes M, Donaldson B, et al. Update on
 Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors. Front Immunol.
 2020;11:1920.

389 15. Relman DA. Maternal IgA: Matchmaking in Early Childhood. Immunity. 2019;51(2):211390 3.

391 16. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental

transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.

Fouda GG, Martinez DR, Swamy GK, Permar SR. The Impact of IgG transplacental
 transfer on early life immunity. Immunohorizons. 2018;2(1):14-25.

395 18. Beudeker CR, Vijlbrief DC, van Montfrans JM, Rooijakkers SHM, van der Flier M.

396 Neonatal sepsis and transient immunodeficiency: Potential for novel immunoglobulin therapies?

397 Front Immunol. 2022;13:1016877.

Flannery DD, Edwards EM, Coggins SA, Horbar JD, Puopolo KM. Late-Onset Sepsis
Among Very Preterm Infants. Pediatrics. 2022;150(6).

400 20. Mwananyanda L PC, Mwansa J, Cowden C, Localio AR, Kapasa ML, Machona S,
401 Musyani CL, Chilufya MM, Munanjala G, Lyondo A, Bates MA, Coffin SE, Hamer DH
402 Preventing Bloodstream Infections and Death in Zambian Neonates: Impact of a Low-cost
403 Infection Control Bundle. Clin Infect Dis. 2019;69(8):1360-7.

404 21. CDC/NHSN Surveillance Definitions for Specific Types of Infections 2024.

405 22. Adam BW, Hall EM, Sternberg M, Lim TH, Flores SR, O'Brien S, et al. The stability of

406 markers in dried-blood spots for recommended newborn screening disorders in the United States.
407 Clin Biochem. 2011;44(17-18):1445-50.

408 23. Bjorkesten J, Enroth S, Shen Q, Wik L, Hougaard DM, Cohen AS, et al. Stability of 409 Proteins in Dried Blood Spot Biobanks. Mol Cell Proteomics. 2017;16(7):1286-96.

410 24. Palmer EA, Cooper HJ, Dunn WB. Investigation of the 12-Month Stability of Dried Blood
411 and Urine Spots Applying Untargeted UHPLC-MS Metabolomic Assays. Anal Chem.
412 2019;91(22):14306-13.

413 25. Zheng W, Zhao W, Wu M, Song X, Caro F, Sun X, et al. Microbiota-targeted maternal 414 antibodies protect neonates from enteric infection. Nature. 2020;577(7791):543-8.

26. Zeng MY, Cisalpino D, Varadarajan S, Hellman J, Warren HS, Cascalho M, et al. Gut
Microbiota-Induced Immunoglobulin G Controls Systemic Infection by Symbiotic Bacteria and
Pathogens. Immunity. 2016;44(3):647-58.

418 27. Bertani B, Ruiz N. Function and Biogenesis of Lipopolysaccharides. EcoSal Plus. 419 2018;8(1).

420 28. Llewelyn M, Cohen J. Anti-Endotoxin Antibodies in Sepsis: A Critical Evaluation. Sepsis.
421 1999;3: 39–45.

422 29. Collingwood A, Blostein F, Seekatz AM, Wobus CE, Woods RJ, Foxman B, et al.
423 Epidemiological and Microbiome Associations Between Klebsiella pneumoniae and Vancomycin-

424 Resistant Enterococcus Colonization in Intensive Care Unit Patients. Open Forum Infect Dis.
 425 2020;7(1):ofaa012.

30. Stach SC, Brizot ML, Liao AW, Palmeira P, Francisco RP, Carneiro-Sampaio MM, et al.
Placental transfer of IgG antibodies specific to Klebsiella and Pseudomonas LPS and to group B
Streptococcus in twin pregnancies. Scand J Immunol. 2015;81(2):135-41.

429 31. Silveira Lessa AL, Krebs VL, Brasil TB, Pontes GN, Carneiro-Sampaio M, Palmeira P.

430 Preterm and term neonates transplacentally acquire IgG antibodies specific to LPS from Klebsiella

431 pneumoniae, Escherichia coli and Pseudomonas aeruginosa. FEMS Immunol Med Microbiol.

432 2011;62(2):236-43.

433 32. Pereira RA, de Almeida VO, Vidori L, Colvero MO, Amantea SL. Immunoglobulin G and
434 subclasses placental transfer in fetuses and preterm newborns: a systematic review. J Perinatol.
435 2023;43(1):3-9.

436 33. Li W, Tse FL. Dried blood spot sampling in combination with LC-MS/MS for quantitative

437 analysis of small molecules. Biomed Chromatogr. 2010;24(1):49-65.

438 34. Garcia Boy R, Henseler J, Mattern R, Skopp G. Determination of morphine and 6-

439 acetylmorphine in blood with use of dried blood spots. Ther Drug Monit. 2008;30(6):733-9.



Fig 1



Fig 2





Sepsis



Figure 4

Fig 4



Fig S1





Fig S2









Fig S4



